Malignant solid neoplasm, ERBB3-mutated
Jump to navigation
Jump to search
1 regimens on this page
1 variants on this page
|
Note: this is a new type of page for HemOnc.org, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.
All lines of therapy
Neratinib monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Hyman et al. 2018 (SUMMIT) | Non-randomized basket trial |
Note: the cycle length is not described in the manuscript; the authors have been contacted for clarification.
Eligibility criteria
- HER2 or HER3 mutations
Chemotherapy
- Neratinib (Nerlynx) 240 mg PO once per day
Supportive medications
- Loperamide (Imodium) (dose not specified) mandatory during cycle 1
28-day cycles
References
- SUMMIT: Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194. Epub 2018 Jan 31. link to original article contains verified protocol link to PMC article PubMed